TABLE 4.
Clinical, Biological, and Radiological Features in Patients Surviving PML (n = 5) and in Patients Dying Because of PML or Another Infection Related to Immune Suppression (n = 4)
| Characteristic | Survivors (n = 5) | Deceased (n = 4) |
|---|---|---|
| Age, yr, median (range) | 55 | 60 |
| Male gender, n (%) | 3 of 5 (60) | 3 of 4 (75) |
| Median delay from diagnosis to T cell therapy, mo | 4.7 | 2.3 |
| Median modified Rankin Score at T cell therapy | 4 | 3.5 |
| Median CD4+ cell count at PML diagnosis, cells/mm3 | 94 | 82 |
| Median JC viral load in the CSF at diagnosis, copies/ml | 384 | 1,870 |
| Median percentage variation in the size of PML lesions at last available MRI | −25 | +258 |
| Subcortical rim of T2* hypointensity before or during treatment, n (%) | 4 of 5 (80) | 2 of 4 (50) |
| Development of punctate contrast enhancement on MRI before and/or during T cell therapy, n (%) | 5 of 5 (100) | 1 of 4 (25) |
CSF = cerebrospinal fluid; MRI = magnetic resonance imaging; PML = progressive multifocal leukoencephalopathy.